HMG CoA reductase inhibitor. Prepn: Y. Fujikawa et al., EP 304063; eidem, US 5011930 (1989, 1991 both to Nissan Chem. Ind.). Prepn of lactone: S. Takano et al., Tetrahedron: Asymmetry 4, 201 (1993). Chiral synthesis: M. Suzuki et al., Bioorg. Med. Chem. Lett. 9, 2977 (1999). Structure-activity study: idem et al., Bioorg. Med. Chem. 9, 2727 (2001). Pharmacology: T. Aoki et al., Arzneim.-Forsch. 47, 904 (1997). HPLC determn in plasma: J. Kojima et al., J. Chromatogr. B 724, 173 (1999). Metabolism: I. Yamada et al., Xenobiotica 33, 789 (2003). Clinical comparison with pravastatin: Y. Saito et al., Atherosclerosis 162, 373 (2002). Clinical evaluation in hypercholesterolemia: S. Park et al., Clin. Ther. 27, 1074 (2005). Review of pharmacokinetics and clinical experience: K. Kajinami et al., Cardiovasc. Drug Rev. 21, 199-215 (2003); R. Y. A. Mukhtar et al., Int. J. Clin. Pract. 59, 239-252 (2005).
Antilipemic.
Antilipemic; HMG CoA Reductase Inhibitors; HMG CoA Reductase Inhibitor